Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature
Pourquoi ce travail est-il dans la base ?
Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.
Le tri à trois modèles
les 1 000 travaux triés →Les trois modèles l'ont jugé hors champ.
Case report plus systematic review of a drug's efficacy in a rare syndrome; clinical question.
This systematic review evaluates a treatment for a clinical syndrome rather than evidence synthesis methodology.
Clinical review of eculizumab in catastrophic antiphospholipid syndrome, not metaresearch.
Résumé
Objective The purpose of this study was to characterize the role of eculizumab, a monoclonal antibody against the terminal complement component C5, in patients with catastrophic antiphospholipid syndrome (CAPS). Methods We present a case report of a patient with systemic lupus erythematosus (SLE) and CAPS treated with eculizumab, as well as results of a systematic review of the literature. Results Including our patient, we identified 11 case reports of patients with CAPS treated with eculizumab. All of them had partial or total remission of symptoms. Conclusion Data on eculizumab efficacy in CAPS are promising but are limited to single case reports. More studies are needed to develop evidence-based recommendations for eculizumab use in CAPS.
Conservé avec la notice de tri, où il sert de preuve aux étiquettes ci-dessus.
La notice
- Revue
- Lupus
- Thématique
- Systemic Lupus Erythematosus Research
- Domaine
- Medicine
- Établissements canadiens
- McMaster University
- Organismes subventionnaires
- —
- Mots-clés
- EculizumabThrombotic microangiopathyMedicineAntiphospholipid syndromeCatastrophic antiphospholipid syndromeAtypical hemolytic uremic syndromeMonoclonalInternal medicineComplement systemIntensive care medicineImmunologyMonoclonal antibodyAntibodyDisease
- Résumé présent dans OpenAlex
- oui